MRNA stock forecast, quote, news & analysis
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018... Show more
Why Moderna (MRNA) Stock Is Up +41% in the Last 30 Days
Key Takeaways
- Moderna (MRNA) climbed roughly 41% over the last 30 days, rising from about $145.55 to around $205, extending a multi-month rally.
- The advance largely reflects follow-through from August's landmark Phase 3 melanoma results for Moderna's individualized cancer therapy, intismeran autogene, developed with Merck.
- Over the last quarter, the stock has more than doubled, moving from the low-to-mid $70s in early July to roughly $205.
- Investor sentiment remains divided: shares hit a 52-week intraday high near $209 in late September, while Citigroup downgraded the stock to Sell on valuation concerns.
- Upcoming full data disclosures, regulatory filings, and quarterly earnings are the key swing factors ahead.
Moderna (MRNA) Company Overview and Market Position
Moderna is a Cambridge, Massachusetts-based biotechnology company and a pioneer in messenger RNA (mRNA) medicine. The company rose to prominence with Spikevax, its COVID-19 vaccine, and has since expanded into an infectious-disease franchise that now includes five approved products, including mFLUSIVA, the first mRNA-based seasonal flu vaccine cleared by the U.S. Food and Drug Administration (FDA).
The company's strategic focus is increasingly on oncology. Its lead oncology asset, intismeran autogene (mRNA-4157/V940), is a personalized, mRNA-based individualized neoantigen therapy being developed in collaboration with Merck & Co. (MRK) for use alongside Merck's immunotherapy Keytruda. Investors follow MRNA closely because the platform's success in cancer could transform the company from a declining vaccine business into a diversified oncology franchise.
Moderna (MRNA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MRNA advanced approximately 41%, from a closing level near $145.55 to around $205. The move was not linear: shares climbed to a 52-week intraday high near $208.90 in late September before pulling back following an analyst downgrade, then rebounded to roughly $205 in early October.
The quarterly picture is even more pronounced. In early July the stock traded between roughly $72 and $82, and it dipped into the mid-$50s later that month amid weak near-term fundamentals. The August 19 catalyst — positive Phase 3 melanoma data — sent shares up 177% in a single session to about $174, and the stock has since consolidated and extended higher, leaving it more than double its early-July levels.
What Drove MRNA Stock Price in the Last 30 Days
The 30-day advance was primarily a continuation of the re-rating that began in August. Investors continued to price in the potential of intismeran autogene, which is being evaluated across multiple tumor types, including lung, bladder, and kidney cancers, beyond its initial melanoma success.
Late September brought a surge to new highs, with shares reaching a 52-week intraday peak near $208.90. That momentum was interrupted on September 30, when Citigroup downgraded MRNA to Sell from Neutral, raising its price target to $80 from $60 while arguing the valuation is difficult to justify. The firm's analysts estimated that even a 100% probability of success on the lead oncology programs supports only about $100 per share. The same day, Moderna announced management changes, appointing Juan Andres as Chief Operating Officer effective October 5, signaling preparation for a potential commercial scale-up of intismeran autogene. Despite the downgrade, shares recovered to roughly $205 in early October, reflecting persistent buyer interest.
What Drove MRNA Stock Performance Over the Last Quarter
The quarter's defining event was August 19, when Moderna and Merck reported that the Phase 3 INTerpath-001 trial of intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and its secondary endpoint of distant metastasis-free survival in patients with resected high-risk melanoma. The stock surged 176.97% in a single day — among the largest one-day gains for an S&P 500 stock in 25 years — and lifted the shares of mRNA peers such as BioNTech (BNTX).
Earlier in August, Moderna received FDA approval for mFLUSIVA, its seasonal flu vaccine for adults 50 and older, marking the company's fifth approved product and the first FDA-approved mRNA flu vaccine. The company also secured supplemental FDA approvals for updated formulations of its Spikevax and mNEXSPIKE COVID-19 vaccines. These milestones reinforced the narrative that mRNA technology extends well beyond COVID-19, even as the underlying business remained unprofitable, with second-quarter 2026 revenue of about $145 million and a GAAP net loss near $800 million.
Trending AI Robots
For investors seeking a systematic way to track momentum across thousands of stocks, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading bots. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. Each bot differs in strategy, timeframe, and performance metrics, allowing traders to compare approaches that range from short-term swing signals to longer-horizon trend-following models. The page is designed to help users identify currently active, high-relevance strategies rather than manually sifting through the full bot catalog. Exploring the section can provide a useful starting point for those interested in data-driven trading tools.
MRNA Stock Forecast Drivers: What Investors Should Watch Next
Several near-term catalysts could shape MRNA's trajectory. Investors are watching for full Phase 3 data presentations from the melanoma trial, with additional details expected at upcoming medical conferences. The next milestone is a potential regulatory filing with the FDA, with management indicating approval could be possible in 2027. Longer-term, overall survival data is not expected until later this decade.
Valuation remains the central point of debate. Wall Street's consensus rating is Hold, with an average price target near $120, well below the current share price — reflecting skepticism about whether clinical success can translate into revenue sufficient to support the stock's roughly $80 billion market capitalization. Upcoming quarterly earnings, guidance updates, the ramp of the flu vaccine franchise, and any additional pipeline readouts across oncology will be closely monitored. These factors present both opportunity and risk, and investors should evaluate them carefully before making decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for MRNA turns positive, indicating new upward trend
MRNA saw its Momentum Indicator move above the 0 level on September 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 73 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 213 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 94 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 2 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.655) is normal, around the industry mean (26.780). P/E Ratio (26.455) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology